Company intelligence / Profile preview

Paganini Biopharma

California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Paganini Biopharma developed an anti-EMP2 monoclonal antibody (ONCR-201) that demonstrated striking anti-tumor effects in preclinical models. In preclinical studies, the antibody significantly reduced primary and secondary tumor load, expression of cancer stem cell markers, and demonstrated survival benefits extending beyond cessation of treatment.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

OncoResponse

Beyond the preview

Go deeper on Paganini Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paganini Biopharma.

Explore the full profile